Bliss Gvs Pharma Share Price
Sector: Biotechnology & Drugs
157.05 +8.25 (5.54%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
147.60
Today’s High
159.25
52 Week Low
101.00
52 Week High
184.95
157.68 +8.87 (5.96%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
148.32
Today’s High
159.25
52 Week Low
101.01
52 Week High
185.50
Key Metrics
- Market Cap (In Cr) 1652.62
- Beta 1.11
- Div. Yield (%) 0.32
- P/B 1.58
- TTM P/E 14.69
- Sector P/E 22.43
- D/E 0
- Open Price 147.6
- Prev Close 148.8
Bliss Gvs Pharma Analysis
Price Analysis
-
1 Week13.9%
-
3 Months33.88%
-
6 Month-1.87%
-
YTD-4.27%
-
1 Year54.68%
Risk Meter
- 54% Low risk
- 54% Moderate risk
- 54% Balanced Risk
- 54% High risk
- 54% Extreme risk
Bliss Gvs Pharma News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
2 min read . 28 Nov 2024Bliss Gvs Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 809.73
- Selling/ General/ Admin Expenses Total
- 112.05
- Depreciation/ Amortization
- 29.42
- Other Operating Expenses Total
- 157.3
- Total Operating Expense
- 712.46
- Operating Income
- 97.27
- Net Income Before Taxes
- 125.64
- Net Income
- 84.3
- Diluted Normalized EPS
- 7.95
- Period
- 2025
- Total Assets
- 1300.84
- Total Liabilities
- 250.46
- Total Equity
- 1050.38
- Tangible Book Valueper Share Common Eq
- 98.93
- Period
- 2025
- Cashfrom Operating Activities
- 105.91
- Cashfrom Investing Activities
- -75.44
- Cashfrom Financing Activities
- -30.34
- Net Changein Cash
- 0.23
- Period
- 2024
- Total Revenue
- 770.24
- Selling/ General/ Admin Expenses Total
- 180.85
- Depreciation/ Amortization
- 26.38
- Other Operating Expenses Total
- 12.5
- Total Operating Expense
- 675.2
- Operating Income
- 95.05
- Net Income Before Taxes
- 116.87
- Net Income
- 75.45
- Diluted Normalized EPS
- 9.02
- Period
- 2024
- Total Assets
- 1213.87
- Total Liabilities
- 246.68
- Total Equity
- 967.19
- Tangible Book Valueper Share Common Eq
- 91.64
- Period
- 2024
- Cashfrom Operating Activities
- 152.45
- Cashfrom Investing Activities
- -132.82
- Cashfrom Financing Activities
- -20.89
- Net Changein Cash
- -1.42
- Period
- 2023
- Total Revenue
- 751.59
- Selling/ General/ Admin Expenses Total
- 183.25
- Depreciation/ Amortization
- 18.67
- Other Operating Expenses Total
- 20.78
- Total Operating Expense
- 652.94
- Operating Income
- 98.65
- Net Income Before Taxes
- 106.07
- Net Income
- 70.86
- Diluted Normalized EPS
- 6.69
- Period
- 2023
- Total Assets
- 1156.85
- Total Liabilities
- 272.96
- Total Equity
- 883.9
- Tangible Book Valueper Share Common Eq
- 84.1
- Period
- 2023
- Cashfrom Operating Activities
- 34.31
- Cashfrom Investing Activities
- -7.75
- Cashfrom Financing Activities
- -24.94
- Net Changein Cash
- 3.02
- Period
- 2022
- Total Revenue
- 747.45
- Selling/ General/ Admin Expenses Total
- 174.96
- Depreciation/ Amortization
- 17.33
- Other Operating Expenses Total
- 33.31
- Total Operating Expense
- 720.04
- Operating Income
- 27.42
- Net Income Before Taxes
- 54.17
- Net Income
- 15.04
- Diluted Normalized EPS
- 4.42
- Period
- 2022
- Total Assets
- 1108.75
- Total Liabilities
- 290.04
- Total Equity
- 818.7
- Tangible Book Valueper Share Common Eq
- 78.19
- Period
- 2022
- Cashfrom Operating Activities
- 135.48
- Cashfrom Investing Activities
- -92.98
- Cashfrom Financing Activities
- -23.73
- Net Changein Cash
- 8.85
- Period
- 2021
- Total Revenue
- 577.21
- Selling/ General/ Admin Expenses Total
- 114.93
- Depreciation/ Amortization
- 17.23
- Other Operating Expenses Total
- 8.15
- Total Operating Expense
- 487.76
- Operating Income
- 89.45
- Net Income Before Taxes
- 104.13
- Net Income
- 68.49
- Diluted Normalized EPS
- 6.5
- Period
- 2021
- Total Assets
- 1076.79
- Total Liabilities
- 268.53
- Total Equity
- 808.25
- Tangible Book Valueper Share Common Eq
- 77.56
- Period
- 2021
- Cashfrom Operating Activities
- 63.97
- Cashfrom Investing Activities
- -46.99
- Cashfrom Financing Activities
- -20.8
- Net Changein Cash
- -2.21
- Period
- 2020
- Total Revenue
- 689.31
- Selling/ General/ Admin Expenses Total
- 104.24
- Depreciation/ Amortization
- 12.59
- Other Operating Expenses Total
- 7.79
- Total Operating Expense
- 591.96
- Operating Income
- 97.35
- Net Income Before Taxes
- 128.97
- Net Income
- 97.27
- Diluted Normalized EPS
- 10.36
- Period
- 2020
- Total Assets
- 1027.22
- Total Liabilities
- 291.61
- Total Equity
- 735.61
- Tangible Book Valueper Share Common Eq
- 70.51
- Period
- 2020
- Cashfrom Operating Activities
- 46.75
- Cashfrom Investing Activities
- -47.89
- Cashfrom Financing Activities
- -6.3
- Net Changein Cash
- 0.3
- Period
- 2019
- Total Revenue
- 898.25
- Selling/ General/ Admin Expenses Total
- 55.36
- Depreciation/ Amortization
- 8.94
- Other Operating Expenses Total
- 9.28
- Total Operating Expense
- 747.18
- Operating Income
- 151.07
- Net Income Before Taxes
- 181.91
- Net Income
- 123.72
- Diluted Normalized EPS
- 12.14
- Period
- 2019
- Total Assets
- 904.88
- Total Liabilities
- 258.88
- Total Equity
- 646
- Tangible Book Valueper Share Common Eq
- 61.64
- Period
- 2019
- Cashfrom Operating Activities
- 39.95
- Cashfrom Investing Activities
- -73.52
- Cashfrom Financing Activities
- 16.83
- Net Changein Cash
- -21.91
- Period
- 2025-03-31
- Total Revenue
- 197.99
- Selling/ General/ Admin Expenses Total
- 28.24
- Depreciation/ Amortization
- 8.04
- Other Operating Expenses Total
- 49.23
- Total Operating Expense
- 184.94
- Operating Income
- 13.05
- Net Income Before Taxes
- 23.44
- Net Income
- 15.54
- Diluted Normalized EPS
- 1.46
- Period
- 2025-03-31
- Total Assets
- 1300.84
- Total Liabilities
- 250.46
- Total Equity
- 1050.38
- Tangible Book Valueper Share Common Eq
- 98.93
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 105.91
- Cashfrom Investing Activities
- -75.44
- Cashfrom Financing Activities
- -30.34
- Net Changein Cash
- 0.23
- Period
- 2024-12-31
- Total Revenue
- 210.42
- Selling/ General/ Admin Expenses Total
- 29.76
- Depreciation/ Amortization
- 7.55
- Other Operating Expenses Total
- 36.67
- Total Operating Expense
- 188.18
- Operating Income
- 22.24
- Net Income Before Taxes
- 36.42
- Net Income
- 23.8
- Diluted Normalized EPS
- 2.27
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 217.68
- Selling/ General/ Admin Expenses Total
- 27.51
- Depreciation/ Amortization
- 6.98
- Other Operating Expenses Total
- 33.77
- Total Operating Expense
- 183.18
- Operating Income
- 34.5
- Net Income Before Taxes
- 35.71
- Net Income
- 24.26
- Diluted Normalized EPS
- 2.29
- Period
- 2024-09-30
- Total Assets
- 1282.51
- Total Liabilities
- 272.56
- Total Equity
- 1009.95
- Tangible Book Valueper Share Common Eq
- 95.29
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 47.57
- Cashfrom Investing Activities
- -21.98
- Cashfrom Financing Activities
- -15.4
- Net Changein Cash
- 10.27
- Period
- 2024-06-30
- Total Revenue
- 183.64
- Selling/ General/ Admin Expenses Total
- 26.54
- Depreciation/ Amortization
- 6.85
- Other Operating Expenses Total
- 37.63
- Total Operating Expense
- 156.16
- Operating Income
- 27.48
- Net Income Before Taxes
- 30.07
- Net Income
- 20.7
- Diluted Normalized EPS
- 1.93
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 198.13
- Selling/ General/ Admin Expenses Total
- 35.03
- Depreciation/ Amortization
- 6.85
- Other Operating Expenses Total
- 39.29
- Total Operating Expense
- 205.82
- Operating Income
- -7.7
- Net Income Before Taxes
- -3.95
- Net Income
- -9.15
- Diluted Normalized EPS
- 0.92
- Period
- 2024-03-31
- Total Assets
- 1213.87
- Total Liabilities
- 246.68
- Total Equity
- 967.19
- Tangible Book Valueper Share Common Eq
- 91.64
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 152.45
- Cashfrom Investing Activities
- -132.82
- Cashfrom Financing Activities
- -20.89
- Net Changein Cash
- -1.42
- Period
- 2023-12-31
- Total Revenue
- 200.72
- Selling/ General/ Admin Expenses Total
- 24.29
- Depreciation/ Amortization
- 6.95
- Other Operating Expenses Total
- 30.25
- Total Operating Expense
- 163.98
- Operating Income
- 36.74
- Net Income Before Taxes
- 40.04
- Net Income
- 27.61
- Diluted Normalized EPS
- 2.6
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Bliss Gvs Pharma Technical
Moving Average
SMA
- 5 Day146.62
- 10 Day144.65
- 20 Day141.41
- 50 Day129.76
- 100 Day129.54
- 300 Day136.44
Bliss Gvs Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ttk Health Care
- 1281.5
- 8.3
- 0.65
- 1923
- 991
- 1810.8
- Bajaj Healthcare
- 518.9
- -4.4
- -0.84
- 744.9
- 312.7
- 1640.73
- Bliss Gvs Pharma
- 157.05
- 8.25
- 5.54
- 184.95
- 101
- 1652.62
- Hester Biosciences
- 1868
- 51.25
- 2.82
- 3375.45
- 1246.75
- 1589.69
- Lincoln Pharmaceuticals
- 567.45
- 6.45
- 1.15
- 975
- 500
- 1134.57
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ttk Health Care
- 25.25
- 1.69
- 7.56
- 7.29
- Bajaj Healthcare
- 36.71
- 3.55
- 16
- 8.22
- Bliss Gvs Pharma
- 18.72
- 1.49
- 7.19
- 9.45
- Hester Biosciences
- 53.74
- 4.93
- 11.14
- 11.44
- Lincoln Pharmaceuticals
- 13.7
- 1.68
- 15.87
- 14.56
Bliss Gvs Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-May-25
- Audited Results & Final Dividend
- 28-Jan-25
- Quarterly Results & Others
- 24-Oct-24
- Quarterly Results
- 24-Jul-24
- Quarterly Results
- 02-May-24
- Audited Results & Final Dividend
- 23-Jan-24
- Quarterly Results
- 01-Nov-23
- Quarterly Results
- 01-Aug-23
- Quarterly Results
- 11-May-23
- Audited Results & Final Dividend
- 24-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 31-Jul-25
- 12-May-25
- AGM
- 13-Jun-25
- 13-May-25
- POM
- 25-Jul-24
- 03-May-24
- AGM
- 19-Jul-23
- 12-May-23
- AGM
- 28-Jun-22
- 02-May-22
- AGM
- 21-Sept-21
- 02-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-May-25
- -
- -
- 0.5
- 03-May-24
- -
- 18-Jul-24
- 0.5
- 11-May-23
- -
- 12-Jul-23
- 0.5
- 02-May-22
- -
- 20-Jun-22
- 0.5
- 11-May-21
- -
- 13-Sept-21
- 0.5


